B. Riley Securities resumed coverage on KORU Medical Systems with a new price target
$KRMD
Medical/Dental Instruments
Health Care
B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $4.50 | Overweight → Neutral | Piper Sandler |
| 7/25/2024 | $4.00 | Buy | B. Riley Securities |
| 9/7/2023 | $4.00 | Buy | Lake Street |
| 9/7/2023 | $4.50 | Buy | B. Riley Securities |
| 11/10/2022 | $3.00 → $4.00 | Hold → Buy | Canaccord Genuity |
| 11/10/2022 | $3.00 → $3.50 | Neutral → Overweight | Piper Sandler |
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Eric Schiller, Chief Technology Officer, pursuant to his previously announced employment agreement with the Company dated as of December 11, 2025. Mr. Schiller was granted nonqualified stock options on January 2, 2026 to purchase 232,297 shares of the Company's common stock at an exercise price of $5.70 per share. In addition, on January 2, 2026, Mr. Schiller received 76,426 restricted shares
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for the use of KORU Medical's FreedomEDGE® infusion system to subcutaneously administer PHESGO® (pertuzumab/trastuzumab/hyaluronidase-zzxf), a co-formulated therapy for HER2+ breast cancer.1 The submission represents a key milestone in KORU Medical's strategy to expand the use of the FreedomEDGE® system bey
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across research & development, device engineering, drug–device combination product development, supply chain strategy, and end-to-end product lifecycle management. As Chief Technology Officer, Eric will lead KORU's product development and innovation pipeline and he
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
S-8 - KORU Medical Systems, Inc. (0000704440) (Filer)
8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50
B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across research & development, device engineering, drug–device combination product development, supply chain strategy, and end-to-end product lifecycle management. As Chief Technology Officer, Eric will lead KORU's product development and innovation pipeline and he
BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025. Shar brings more than 25 years of global leadership experience in the medical technology sector, with a proven track record of scaling businesses, driving innovation, and building strong customer partnerships. He most recently served as CEO of Cordis, where he led the successful transformation from a division of Cardinal Health to one of the world's largest pure-play cardiovascular compa
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights • Third quarter 2025 net revenues of $10.4 million, a 27% increase over the prior year period • Core business (Domestic and International) net revenues of $9.8 million, a 30% increase over the prior year period • Announced two new Pharma Services and Clinical Trials (PST) collaborations expanding opportunity to reach new p
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2025 financial results on Wednesday, November 12, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for internatio
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights • Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period • Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period • Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi